Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies [Medical Sciences]
Antigen-directed immunotherapies for acute myeloid leukemia (AML), such as chimeric antigen receptor T cells (CAR-Ts) or antibody-drug conjugates (ADCs), are associated with severe toxicities due to the lack of unique targetable antigens that can distinguish leukemic cells from normal myeloid cells or myeloid progenitors. Here, we present an approach to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Florence Borot, Hui Wang, Yan Ma, Toghrul Jafarov, Azra Raza, Abdullah Mahmood Ali, Siddhartha Mukherjee Tags: PNAS Plus Source Type: research
More News: Academies | Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Genetics | Immunotherapy | Leukemia | Science | Stem Cell Therapy | Stem Cells | Toxicology